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DOI: http://dx.doi.org/10.1016/j.hemonc.2014.09.007PURPOSE: To determine the frequency of PIK3CA mutations in a Peruvian cohort with HER2-amplified and tri-
ple negative breast cancers (TNBC).
METHODS: We analyzed two cohorts of 134 primary non-metastatic breast cancer patients from Peru. Cohorts
consisted of 51 hormone receptors (+)/HER2-amplified breast tumor patients surgically resected as first treatment
included in the ALTTO trial (ALTTO cohort) and 81 TNBC patients with residual disease after neoadjuvant treat-
ment (neoadjuvant cohort). Genomic DNA was extracted from paraffin-embedded tumor samples. Samples from
the ALTTO and neoadjuvant cohorts were taken at biopsies and from residual tumors, respectively. PIK3CA
mutations were detected by sequencing DNA fragments obtained by PCR amplification of exons and their
flanking introns. All of the detected PIK3CA mutations were confirmed in a second independent run of sample
testing.
RESULTS: PIK3CA mutations were present in 21/134 cases (15.7%). Mutations in exon 9 and 20 were present in
10/134 (7.5%) and 11/134 (8.2%), respectively. No cases had mutations in both exons. Mutations in exon 9 con-
sisted of E545A (seven cases), E545K (two cases) and E545Q (one case); while in exon 20, mutations consisted of
H1047R (10 cases) and H1047L (one case). Compared to TNBC patients, HER2-amplified patients were more
likely to have PIK3CA mutated (23% vs 9.6%; P = 0.034). There were no associations between mutational status
of PIK3CA with estrogen receptor status (P = 0.731), progesterone receptor status (P = 0.921), age (P = 0.646),
nodal status (P = 0.240) or histological grade (P = 1.00). No significant associations were found between PIK3CA
mutational status and clinicopathological features.
CONCLUSIONS: We found a similar frequency of PIK3CA mutations to that reported in other series. Although
we did not include HR+/HER2 patients, those with HER2-amplified tumors were more likely to present PIK3CA
mutations compared to patients with triple negative tumors.
KEYWORDS: Breast cancer; PIK3CA; HER2; Triple negativeBreast cancer (BC) is the most frequent canceramong women around the globe and the sec-ond most frequent malignancy in Peruvian
women (age-standardized rate incidence of 34 per
100,000 women each year).1 Latinas represent the
largest (14% of US population), youngest and fast-est-growing minority in the U.S. and around 10% of
developing countries.2 It appears that BC is less pre-
valent but demonstrates higher mortality in Latinas
than in Caucasian women.3–5
BC is a genetically heterogeneous disease and has
signiﬁcant variability among different ethnic and racialarter 2014
FREQUENCY OF PIK3CA MUTATIONS original research report
groups with respect to incidence, clinical characteris-
tics, and prognosis.6 Socio-economic and cultural fac-
tors are among the reasons underlying these
differences. Little information is available for the Lati-
na population.
HER2 is a molecule with the ability to deﬁne BC
behavior and can predict response to anti-HER2
treatment. Its activation and dimerization leads to
downstream activation of many signaling molecules,
including phosphoinositide 3-kinase (PI3K). The
PI3K is a cell pathway related to the regulation of cell
signaling, growth, proliferation, and apoptosis. This
pathway activates the serine/threonine kinase AKT
which in turn activates phosphorylates and regulates
mTOR.7 Several preclinical studies suggest that
HER2-independent activation of the PI3K-AKT
pathway may be related to trastuzumab resistance.8
Preclinical and tumor tissue analysis have indicated
PI3K-AKT pathway is frequently activated in BC;
and its activation has been associated with aggressive
features like high histological grade, basal-like and
HER2 phenotypes, as well as poor clinical outcome.
Most of the mutations in this pathway (80%) happen
at three hotspots of the gene PIK3CA: two in exon 9
and one in exon 20. These mutations are found in
28–40% of BC tumors, and His1047Arg is the most
common mutation. However, their relation to speciﬁc
phenotypes or prognosis in BC is unclear.9
The relevance of this pathway has increased due to
the recently demonstrated beneﬁt of PI3K pathway
modulators in hormone-sensible BC, and to evidence
suggesting these drugs could improve trastuzumab
activity in HER2-positive. Further, recent informa-
tion indicates that PIK3CA mutation status could
predict response to PI3K modulators.9–11
A study by Wu et al. in Los Angeles, US,
found PI3K-AKT pathway activation in >70% in
HER2(+) tumors from African-American and Latina
BC patients, compared to <45% reported for
HER2(+) tumors from Japanese and Swedish
women.12 Liedtke et al. evaluated PIK3CA mutations
in 140 stage II–III BC cases, including 50 Hispanic
cases (mostly from Peru and Mexico). The study
found mutations in 10 cases (six in exon 9 and four
in exon 20) from the 50 Hispanic patients, 10 (six
in exon 9 and four in exon 20) from 74 Caucasian
patients and two (only in exon 20) from 13 Black
patients.13
This information suggests PIK3CA mutation
rates could be higher in a Latina population. We were
therefore determined to evaluate for the ﬁrst-time the
prevalence of PIK3CA mutations in a Peruvian
HER2-ampliﬁed (HER2-amp) and triple-negativeHematol Oncol Stem Cell Ther 7(4) Fourth Quarter 2014BC series, and to compare it with data from other
world regions.METHODS
Patients and samples
We analyzed two cohort samples of 134 primary non-
metastatic breast cancers diagnosed and treated at the
Instituto Nacional de Enfermedades Neoplásicas
(Lima, Peru). The ﬁrst cohort (ALTTO cohort) con-
sisted of 51 patients with ER+ and/or PR+ and
HER2+ tumors surgically resected as ﬁrst treatment
and who were enrolled in the ALTTO trial. The
second cohort consisted of 83 patients with triple
negative breast cancer with residual tumor after the
neoadjuvant treatment. The samples were examined
histologically and were considered suitable for this
study if the proportion of tumor cells exceeded 50%
with sufﬁcient cellularity as was proven by evaluation
of tumor samples stained by hematoxylin and eosine.
Evaluation of ER, PgR, and HER2 status
Estrogen Receptor (ER), Progesterone Receptor
(PgR) and HER2 were evaluated by immunohisto-
chemistry (IHC) on formalin-ﬁxed, parafﬁn-embed-
ded (FFPE) breast tumor samples with the follow
primary antibodies: Anti-Estrogen Receptor ID5
clone (Dako, Carpinteria, CA); Anti-Progesterone
Receptor PGRG36 clone (Dako, Carpinteria, CA);
Anti-HER2, clone A0485 (Dako, Carpinteria, CA).
Antigen retrieval for ER and PR was done with cit-
rate buffer (pH 7.5) with heat for 15 min; while for
HER2, enzymatic digestion with Trypsin was per-
formed at 37 C for 20 min. Steps for IHC were
taken according to the manufacturer’s instructions.
A tumor was considered ER or PR positive if there
was presence of nuclear staining in 1% of tumor
cells; and HER2 was positive if 3 was scored by
immunohistochemistry. A blinded review was con-
ducted by one pathologist (FD).
Additional conﬁrmation by ﬂuorescent in situ
hybridization (FISH) was done in a centralized labo-
ratory in the ALTTO trial context (ALTTO Cohort)
with the conditions described in Ref.14. The HER2
FISH evaluation in the neoadjuvant cohort was per-
formed at the Vanderbilt-Ingram Cancer Center on
FFPE tissues using the PathVysion HER-2 DNA
Probe Kit (PathVysion Kit, Abbott Molecular, Des
Planes, IL, USA) utilizing the Vysis LSI
HER-2/neu 17q11.2–12 SpectrumOrange and
Vysis CEP 17 (17p11.1–q11.1 Spectrum Green
Alpha Satellite DNA) probes. Images were visualized
on a Fluorescence Olympus BX60 Microscope and143
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analyzed using the Genus for Genetic Image Anal-
ysis software, version 3.6 as described in Ref. 15.
PIK3CA mutation screening
Analysis of the ALTTO cohort
FFPE tissue samples containing the rich-tumor region
were identiﬁed by microscopy and the corresponding
region was micro-dissected. Genomic DNAs were
extracted from the tissue samples using the DNeasy
tissue kit (Qiagen, Valencia, CA). The sample was
incubated overnight with Proteinase K at 56 C.
The DNA was bound to silica columns, washed
and eluted in 30 ll of nuclease-free water according
to manufacturer’s instructions. PIK3CA mutations
were detected by screening DNA fragments obtained




TTCAGTTA; PIK3CA-Exon20, Forward: TGAG
CAAGAGGCTTTGGAGT, Reverse: GGTCTTT
GCCTGCTGAGAGT). The ampliﬁed products
were sequenced on an ABI Prism 3130 automated
DNA sequencer (Applied Biosystems, Foster City,
CA), and the sequences of PIK3CA sequencing pro-
ﬁles were compared with the corresponding reference
sequence (NM_006218). All of the detected PIK3CA
mutations were conﬁrmed in a second independent
run of sample testing.
Analysis of the neoadjuvant cohort
Samples were evaluated at Foundation Medicine Inc.
facilities using a high throughput next-generation
sequencing protocol. Brieﬂy, DNA was extracted
from 40 lm of unstained FFPE sections, and then
puriﬁed with the Promega Maxwell 16 Tissue
LEV DNA kit; 50–200 ng of dsDNA were frag-
mented to 200 bp by sonication before puriﬁcation
with AMPure XP beads (Agencourt). SPRI puriﬁca-
tion and subsequent library construction with the
NEBNext kits (E6040S, NEB) containing mixes for
end repair, dA addition and ligation, were performed
in 96-well plates (Eppendorf) on a Bravo Benchbot
(Agilent). Indexed (6-bp barcodes) sequencing
libraries were PCR ampliﬁed with HiFi (Kapa)
for 10 cycles, 1.8X SPRI puriﬁed and quantiﬁed.
Paired end sequencing was performed using the
HiSeq2000 (Illumina). Sequence data from genomic
DNA were mapped to the reference human genome
(hg19) using the BWA aligner. PCR duplicate read
removal and sequence metric collection were per-
formed using Picard (http://picard.sourceforge.net)and SAMtools.16 Local alignment optimization was
performed using GATK.17
Statistical analysis
Relationships between PIK3CA mutation status and
clinical, histological, and biological parameters were
estimated with the chi-squared test. Differences
between the mutated and non-mutated populations
were judged signiﬁcant at conﬁdence levels of greater
than 95% (P < 0.05).
Ethical considerations
Patients in the ALTTO cohort (INEN 07-18) were
informed in the ALTTO trial context and signed an
informed consent stating that their tumor samples
might be used for scientiﬁc purposes and that they
had the opportunity to decline at any time. Patients
on the neoadjuvant cohort were under an institution-
ally approved protocol (INEN 10-018).RESULTS
Patient characteristics
ALTTO cohort
Fifty-one patients had breast conserving surgery or
modiﬁed radical mastectomy as ﬁrst treatment. All
patients received adjuvant chemotherapy with anthra-
cyclines and taxanes. Forty-one patients (80.4%)
received adjuvant radiation. Patients included in the
ALTTO study were treated with adjuvant trast-
uzumab with or without lapatinib.
Neoadjuvant cohort
This cohort comprised 81 patients with TNBC deter-
mined by immunohistochemistry with residual disease
after anthracycline-based neoadjuvant chemotherapy.
After FISH conﬁrmation, eight patients had HER2
ampliﬁcation.
PIK3CA status
PIK3CA mutations were present in 21 cases (15.7%).
Mutations in exon 9 and 20 were present in 10 (7.5%)
and 11 (8.2%) cases, respectively. No case had muta-
tions in both exons or coexistence of two or more
mutations. Mutations in exon 9 were E545A (seven
cases), E545K (two cases) and E545Q (one case);
while in exon 20, mutations were H1047R (10 cases)
and H1047L (one case) (see Table 1).
HER2-amp patients were more likely to have
PIK3CA mutations (23% vs 9.6%; P = 0.034). Dif-
ferences between these two groups were in the exon
9 (P = 0.023). There were no associations betweenHematol Oncol Stem Cell Ther 7(4) Fourth Quarter 2014
Table 1. PIK3CA mutation profiles.
Exon Nucleotide change Amino acid substitution HER2-amp TNBC Total
n (%) n (%) n (%)
9 A1634C E545A 7 (11.5) 0 7 (5.2)
9 G1633A E545K 1 (1.6) 1 (1.4) 2 (1.5)
9 G1633C E545Q 0 1 (1.4) 1 (0.7)
20 A3140G H1047R 6 (9.8) 4 (5.5) 10 (7.5)
20 A3140T H1047L 0 1 (1.4) 1 (0.7)
FREQUENCY OF PIK3CA MUTATIONS original research reportmutational status of PIK3CA with estrogen receptor
status (P = 0.717), progesterone receptor status
(P = 1.000), age (P = 0.808) nodal status (P =
0.432) or histological grade (P = 0.457). No signiﬁ-
cant associations were found between PIK3CA
mutational status and clinicopathological features
according to HER2+ or TNBC subgroups (Table 2).DISCUSSION
This study represents the ﬁrst detailed analysis of
PI3K mutations in a well-deﬁned cohort of Hispanic
patients. In this report we show an overall frequency
of 15.7% of PIK3CA mutations in breast cancer
tumors in a group of patients with HER2-amp and
TNBC. Although the coexistence of two distinct
PI3KCA mutations in the same sample has previously
been reported, all mutations detected in our patients
were unique and there was no coexistence of two or
more mutations.
HER2amp tumors were more likely to have
PIK3CA mutations than TNBC, and the signiﬁcant
difference was in the distribution in mutations in exon
9. Although there is no consensus about a predisposi-
tion of PIK3CA mutation by breast cancer pheno-
types, several reports describe that 12–25% of
HER2+ tumors had mutations in PI3KCA, and that
TNBC harbors low rates of PI3KCA mutations.
Cizkova et al. reported that PIK3CA mutations in
452 patients were more common in HR positive
tumors (39%) and HER2-enriched tumors (25%)
than in basal-like tumors (13%).18 The data of the
Cancer Genome Atlas Network of 507 patients eval-
uated with breast cancer showed a frequency of muta-
tions of PIK3CA in 45% in luminal A, 29% in
luminal B, 39% in HER2-enriched and 9% in basal-
like tumors.19
Jensen et al. evaluated 240 HER2-positive early
BC cases treated with adjuvant chemotherapy andHematol Oncol Stem Cell Ther 7(4) Fourth Quarter 2014trastuzumab and found PIK3CA mutations in 26%
of patients and whose survival rates had worse out-
come.20 A retrospective analysis of PIK3CA muta-
tions in 107 HER2-positive metastatic breast cancer
detected a 22% rate of mutations with a correlation
with worse TTP (median 7.6 vs 11.3 months) and
OS (median 20.1 vs 41.0 months, P = 0.046).21
A previous report by Cizkova et al. describes more
favorable metastases-free survival (MFS) in patients
with PIK3CA mutations (ﬁve-year MFS of 81.0%
versus 69.6% and 15-year MFS of 65.8% versus
53.4% for PIK3CA mutated vs wild type, respec-
tively). Although some reports do not ﬁnd prognostic
relevance for the presence of PIK3CA mutation, it
has been described as a PIK3CA mutation-associated
gene expression signature predicting favorable survival
in ER-positive breast cancer.18,22
Recently, Baselga et al. evaluated the role of
PIK3CA mutations in approximately 800 naive
HER2-positive metastatic BC cases included in the
phase III clinical trial CLEOPATRA (trastuzumab
with or without pertuzumab). They found that these
mutations were associated with worse prognosis
(P = 0001) and without difference in relation to the
treatment arm.23
Analysis of the predictive value of PIK3CA
mutations on anti-HER2 agents was performed in a
biomarker analysis of around 200 patients included
in the phase II study of neoadjuvant pertuzumab
and trastuzumab, with ﬁndings of PIK3CA muta-
tions in 24% of patients and not associated with
pCR.24
There is also evidence showing that tumors with
PI3K/AKT pathway activation including PTEN loss
or PIK3CA mutation or both are less sensitive to
trastuzumab treatment.21 Interestingly, this resistance
appears to be reversed by mammalian target of rapa-
mycin (mTOR) or PI3K inhibitors.25 A ﬁnal valida-
tion of PIK3CA mutation as an independent145
Table 2. Relationship between PIK3CA mutation status and standard clinical, pathological and biological features of breast cancer.
Patient features n Exon 9 Exon 20 Any exon 19 or 20 Pa
Age in years
<50 74 (55.2%) 5 (6.8%) 7 (9.6%) 12 (16.2%) 0.847
50 60 (44.8%) 5 (8.3%) 4 (6.8%) 9 (15%)
Histological gradeb
II 14 (26.4%) 3 (21.4%) 0 3 (21.4%) 1
III 39 (73.6%) 4 (10.3%) 4 (10.3%) 8 (20.5%)
Lymph node statusb
0 16 (30.2%) 2 (12.5%) 2 (12.5%) 4 (25%) 0.240
1–3 16 (30.2%) 3 (18.8%) 2 (12.5%) 5 (31.3%)
>3 21 (39.6%) 2 (9.5%) 0 2 (9.5%)
Nodal involvement after chemoc
Positive 25 (31.6%) 1 (4.0%) 3 (12.0%) 4 (16%) 0.453
Negative 54 (68.4%) 1 (1.9%) 4 (7.4%) 5 (9.3%)
NA 2
Tumor sizeb
<2 cm 10 (22.2%) 2 (20%) 1 (10%) 3 (30%) 0.393
>2 cm 35 (77.8%) 4 (11.4%) 2 (5.7%) 6 (17.1%)
Not evaluable 8 1
ER status
Negative 117 (75.5%) 8 (6.8%) 10 (8.5%) 18 (15.4%) 0.731
Positive 17 (24.5%) 2 (11.8%) 1 (5.9%) 3 (17.6%)
PR status
Negative 122 (91.1%) 9 (7.4%) 10 (8.2%) 19 (15.6%) 0.921
Positive 12 (9.0%) 1 (8.3%) 1 (8.3%) 2 (16.7%)
Phenotype
TNBC 73 (75.5%) 2 (2.7%) 5 (6.8%) 7 (9.6%) 0.034
HER2-amp 61 (24.5%) 8 (13.1%) 6 (9.8%) 14 (23.0%)
aP-value for the Chi-square or Fisher test.bFor the ALTTO cohort.
cFor the neoadjuvant cohort.
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ERBB2+ breast cancer needs a prospective random-
ized study.
Our results describe the presence of PIK3CA
mutation in Peruvian women with breast cancer.
Due to the prospective nature of our study, and a
short period of follow-up, no conclusion on survival
could be obtained. However, our data show that the
association of PIK3CA mutations with the phenotype
is present across different ethnic groups. Previousgenomic analyses were performed almost entirely on
populations of European descent. It is possible that
speciﬁc differences in the genomic architecture of cer-
tain populations may inﬂuence the outcome of BC.
The type and frequency of PI3K mutations in other
subtypes of BC in this Hispanic population is yet to
be evaluated. Moreover, studies that assess the prog-
nostic and predictive value of alterations in PI3K
pathways in different ethnic groups deserve further
analysis (see Table 3).Hematol Oncol Stem Cell Ther 7(4) Fourth Quarter 2014
Table 3. Diverse mutations in diverse ethnic groups.
N Any
exon (%)
Exon 9 Exon 20 Subset
Present study
(Hispanic)
134 20.7 E545A, E545K, E545Q H1047R, H1047L HER2amp (23% mut); TNBC (9.6% mut)
Liedtke et al.13 140 16 E542K, E542V, E545K, Q546R H1047R, H1047T, G1049R CS II-III, all subtypes ER+ (19.2% mut); PR+






45 12.2 D549N H1048Y, A987V, M1004I, H1048Y, L1026P HER2+ Met
Jensen et al.20
(Caucasian)









151 33.4 E545A, Q546A, E542K, E545G, E545K, E545Q,
N497S, Q546K, Q546R
N1044K, G1049R, T1052K, D1029H,
H1047R, A1066V, M1043V
All subtypes Era+(39.1% mut); PR (41.4% mut);
HER2+ (24.7%)
Abbreviations: TNBC, triple negative breast cancer; amp, amplified; mut, mutated PIK3CA; met, metastatic; ER, estrogen receptor; PR, progesterone receptor.
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